Effectiveness of palivizumab to prevent hospitalization for respiratory syncytial virus infection in preterm infants 321 to 35° weeks' gestation in Spain;Efectividad de palivizumab en la prevención de la infección por el virus respiratorio sincitial en prematuros de 321 a 35° semanas de gestación en España

Acta Pediatrica Espanola

Volumn 68, Issue 1, 2010, Pages 13-18

  Figueras Aloy, J ^a   Carbonell Estrany, X ^a   Quero Jimenez J ^b   Fernandez Colomer B ^c   Guzman Cabanas J ^d   Echaniz Urcelay, I ^e   Domenech Martinez E ^f   Ripoll, Luis Moltó ^g   Monasterolo, Ricardo Closa ^h   Zaballos, M Francisca Benito ⁱ   Demestre, Xavier ^a   Bejarano, M José Hernández ^j   Calvo, José Luis Fernández ^k   Krauel, Xavier ^l   Millán, Leticia ^m   Gonźalez, José Quero ^b   Perales, Antonio Bonillo ⁿ   Narbona, Eduardo ^o   Echevarría, Itziar ^p   Rodríguez, Adela Ana ^q   Pérez, Guadalupe ^r   Gutiérrez, Andrés Martinez ^s   Crespo, María Jesus Ripalda ^t   Sánchez Luna, Manuel ^u   Malfaz, Fernando Centeno ^v   Grisolia, Luis Paisán ^w   Muñoz, M José Santos ^x   García, Francisco Guerra ^y   Sastre, José Lopez ^c   García Del Rio, Manuel ^z   Cabañas, Juana Guzman ^aa   Doménech, Eduardo ^f   Galiana, Gemma Ginovart ^ab   Benjumea, Antonio Gutiérrez ^ac   Mendivil, Carmen ^ad   Fraga, José Maria ^ae   Abizanda, Salvador Salcedo ^af   Novoa, Gemma ^ag   Trisac, José Luis Fernández ^ah   Gonzalez, Ernesto J Perez ^ai   Paredes, Carlos ^aj   Echániz, Inigo ^e   Romera, Gerardo ^ak   Ortiz, Joaquiri ^al   Roqués, Vicente ^am   Aloy, Josep Figueras ^a   more..

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^e HOSPITAL DE BASURTO   (Spain)

^f HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^h HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

ⁱ HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^j HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^k HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^l HOSPITAL SANT JOAN DE DÉU   (Spain)

^m Hospital Sant Joan de Déu ^*  (Spain)

ⁿ HOSPITAL TORRECÁRDENAS   (Spain)

^o HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^p HOSPITAL TXAGORRITXU   (Spain)

^q HOSPITAL DE CABUEÑES   (Spain)

^r HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^s HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^t HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^u HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^v HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^w HOSPITAL DONOSTIA   (Spain)

^x HOSPITAL SEVERO OCHOA   (Spain)

^y HOSPITAL DE MÓSTOLES   (Spain)

^z Hospital Materno Infantil de Málaga   (Argentina)

^aa Hospital Universitario Reina Sofia Cordoba   (Argentina)

^ab HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^ac HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^ad Universidad Pública de Navarra   (Spain)

^ae HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^af HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^ag Department of Rheumatology   (Spain)

^ah HOSPITAL JUAN CANALEJO   (Spain)

^ai HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^aj HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^ak Hospital Madrid Monteprincipe   (Spain)

^al HOSPITAL DE JEREZ   (Spain)

^am HOSPITAL UNIVERSITARIO LA FE   (Spain)

more..

Author keywords

Hospitalization; Palivizumab; Preterm infants; Respiratory syncytial virus; Tobacco smoking habit

Indexed keywords

CASPASE 10; PALIVIZUMAB;

AGE DISTRIBUTION; ARTICLE; BIRTH WEIGHT; DAY CARE; DRUG EFFICACY; GESTATIONAL AGE; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MATERNAL SMOKING; PREMATURITY; RISK FACTOR; SEASONAL VARIATION; VIRUS INFECTION;

EID: 77249103063     PISSN: 00016640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Groothuis JR, Gutiérrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics. 1988;82:199-203.
2. Carbonell-Estrany J, Quero J, Figueras J, García-Alix A, Alomar A, Blanco D, et al. Recomendaciones para la preventión de la infección por virus respiratorio sincitial. An Esp Pediatr. 2000;52: 372-374.
3. Carbonell-Estrany X, Quero Jiménez J; Comité de Estándares de la SEN. Recomendaciones para la prevención de la infection por virus respiratorio sincitial: revisión. An Esp Pediatr. 2002;56:334-336.
4. Figueras J, Quero J; Comisión de estándares de la Sociedad Española de Neonatología. Recomendaciones para la prevención de la infección por virus respiratorio sincitial. An Pediatr (Barc). 2005; 63:357-362.
5. Bonillo A, Díez Delgado J, Ortega A, Infante P, Jiménez M, Battles J, et al. Antecedentes perinatales y hospitalización por bronquiolitis. Comparación con el Impact RSV Study Group. An Esp Pediatr. 2000;53:527-532.
6. González H, García F, Fernández J, Izquierdo B, Pino A, Blanco A. Estudio clinicoepidemiológico de la bronquiolitis aguda. An Esp Pediatr. 2000;53:520-526.
7. Figueras-Aloy J, Carbonell-Estrany X, Quero-Jiménez J, Fernández-Colomer B, Guzmán-Cabañas J, Echaniz-Urcelay I, et al. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J. 2008; 27: 788-793.
8. Horn SD, Smout RJ. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr. 2003;143: 133S-141S.
9. Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr. 2003; 143:150S-156S.
10. Embleton ND, Harkensee C, Mckean MC. Palivizumab for preterm infant. Is it worth it? Arch Dis Child Fetal Neonatal Ed. 2005; 90: 286F-289F.
11. Duppenthaler A, Gorgievski-Hrisoho M, Aebi C. Regional impact of prophylaxis with the monoclonal antibody palivizumab on hospitalisations for respiratory syncytial virus in infants. Swiss Med Wkly. 2001;131:146-151.
12. Wegner S, Vann JJ, Liu G, Byrns P, Cypra C, Campbell W, et al. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina medicaid program. Pediatrics. 2004;114:1.612-1.619.
13. Figueras-Aloy J, Carbonell-Estrany X, Quero J; IRIS Study Group. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J. 2004;23:815-820.
14. 1 a 35° semanas de gestación en España. An Pediatr (Barc). 2009;71:47-53.
15. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531-537.
16. Doménech JM. Bioestadĩstica. Métodos estadĩsticos para investigadores. Barcelona: Herder, 1977.
17. Carbonell-Estrany X, Quero J, Bustos G, et al. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. Pediatr Infect Dis J. 2000;19:592-597.
18. Carbonell-Estrany X, Quero J; IRIS Study Group. Hospitalization rates for respiratory syncytial virus (RSV) infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J. 2001;20:874-879.
19. Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J; IRIS Study Group. Effectiveness of palivizumab prophylaxis in decreasing syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J. 2003;22:823-827.
20. González de Dios J, Ochoa C. La profilaxis frente al virus respiratorio sincitial con anticuerpos monoclonales (palivizumab). Una panorámica a través de la medicina basada en la evidencia. Rev Esp Pediatr. 2003;59:391-402.
21. Wang D, Cummins C, Bayliss S, Sandercock J, Burls A. Immunoprohylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technol Assess. 2008;12(36).
22. Romero R. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Pediatr Infect Dis J. 2003;22 Supl 2:46-54.
23. Korppi M. Palivizumab prophylaxis: how to compare pre- and postprophylaxis eras? Pediatr Pulmonol. 2007;42:660.
24. Feltes TF, Cabalka AK, Meissner C, Piazza FM, Carlin DA, Top FH Jr, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143:532-540.
25. González de Dios J, Ochoa Sangrador C, Balaguer Santamaría A. La profilaxis trente al virus respiratorio sincitial con anticuerpos monoclonales (palivizumab) en cardiopatías congénitas: revisión acrítica de la eficacia. efectividad, eficiencia y seguridad. Rev Pediatr Aten Primaria. 2007;9:71-100.
26. Simoes EAF, Carbonell-Estrany X, Fullarton JR, Liese JG, Figueras-Aloy J, Doering G, et al. A predictive model for respiratory syncytial virus (RSV) hospitalization of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP study. Respiratory Res. 2008;9:78.
27. Law B, Langley JM, Allen U, Paes B, Lee DSC, Mitchell I, et al. The Pediatric Investigators Collaborative Network on Infections in Canada Study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J. 2004;23:806-814.
28. Simoes EAR Immunoprophylaxis of respiratory syncytial virus: global experience. Respir Res. 2002;3 Supl 1:26-33.
29. Lázaro P, Figueras J, Doménech E, Echaniz I, Closa R, Wood MA, et al. La eficiencia (coste-efectividad) de palivizumab como profilaxis para la infección por VRS en prematuros de 32-35 semanas en Espana. An Pediatr (Barc). 2006;65:316-324.